Accuray

ARAY

Market cap $122M

Accuray reported another weak quarter, with revenue and order declines highlighting ongoing struggles amid recent leadership changes. ARAY's gross margin weakened significantly on sales mix, driving EBITDA into the red, and backlog eroded for the sixth consecutive quarter. A new CEO and transformation plan offer potential, but details are scarce and operational improvements remain uncertain amid entrenched competition.

Accuray Incorporated ( ARAY ) Q1 2026 Earnings Call November 5, 2025 4:30 PM EST Company Participants Stephen Monroe Stephen LaNeve - President, CEO & Director Ali Pervaiz - Senior VP & CFO Conference Call Participants Marie Thibault - BTIG, LLC, Research Division Presentation Operator Good day, and welcome to the Accuray First Quarter Fiscal 2026 Financial Results Conference Call. [Operator Instructions].

MADISON, Wis., Nov. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended September 30, 2025.

MADISON, Wis. , Oct. 31, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Stephen La Neve, the company's new Chief Executive Officer.

MADISON, Wis. , Oct. 28, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2026, ended September 30, 2025, during a conference call hosted by company management at 1:30 p.m.

Industry Veteran Steve La Neve Named Chief Executive Officer  Suzanne Winter to Retire as President and CEO Company Appoints Steven F. Mayer as Transformation Board Sponsor Chan W.

5D Clinics and Joint Venture Partner Icon Group Make Strides in Delivering on Commitment to Increasing Access to World-class Radiation Treatments for More Communities Across Australia. MADISON, Wis.

MADISON, Wis. , Sept. 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced today the signing of a memorandum of understanding (MOU) to advance online adaptive radiotherapy (OART) on the Accuray helical radiation treatment delivery platform.

Accuray Incorporated (NASDAQ:ARAY ) Shareholder/Analyst Call September 29, 2025 4:30 PM EDT Company Participants Suzanne Winter - President, CEO & Director Mu Lee - Senior Vice President of Research & Product Development Seth Blacksburg - Senior VP & Chief Medical Officer Conference Call Participants Shalom Kalnicki Jonathan Haas Giuseppe Sasso John Kresl Presentation Suzanne Winter President, CEO & Director Good afternoon, everyone, and welcome to Accuray's Analyst briefing. We're coming to you from the ASTRO conference in San Francisco for 2025.

New Solution Provides an Unprecedented Set of Tools, Empowering Clinical Teams With Choice and Flexibility to Deliver Adaptive Care—Tailoring Radiotherapy to Each Patient's Unique Needs MADISON, Wis. , Sept. 26, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company is advancing its legacy of leadership in adaptive radiotherapy with the introduction of the Accuray Stellar™* Solution.